Drug Trial Radar · NCT04484623
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
302
Actual
Start
Oct 1, 2020
Primary completion
Jan 29, 2024
Study completion Jun 25, 2029
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jul 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple myeloma (RRMM).
Conditions
- Multiple Myeloma
Interventions
Belantamab mafodotinDrug
Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate will be administered.
PomalidomideDrug
Immunomodulatory drug (IMiD) will be administered.
DexamethasoneDrug
Synthetic glucocorticoid with anti-tumor activity will be administered.
BortezomibDrug
Proteasome Inhibitor will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Up to approximately 174 weeks
Locations
122 sites in 18 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Fort Myers, Florida
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Kansas City, Missouri
GSK Investigational Site
Nashville, Tennessee
GSK Investigational Site
Garran, Australian Capital Territory, Australia
GSK Investigational Site
Darlinghurst, New South Wales, Australia
GSK Investigational Site
Gosford NSW, New South Wales, Australia
GSK Investigational Site
Port Macquarie, New South Wales, Australia
GSK Investigational Site
Benowa, Queensland, Australia
GSK Investigational Site
South Brisbane, Queensland, Australia
GSK Investigational Site
Adelaide, South Australia, Australia
GSK Investigational Site
Fitzroy, Victoria, Australia
GSK Investigational Site
Heidelberg, Victoria, Australia
GSK Investigational Site
Malvern, Victoria, Australia
GSK Investigational Site
Nedlands, Western Australia, Australia
GSK Investigational Site
Curitiba, Brazil
GSK Investigational Site
Joinville, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
GSK Investigational Site
Beijing, China
GSK Investigational Site
Beijing, China
GSK Investigational Site
Changchun, China
GSK Investigational Site
Changsha, China
GSK Investigational Site
Guangzhou, China
GSK Investigational Site
Hangzhou, China
GSK Investigational Site
Jiangsu, China
GSK Investigational Site
Nanchang, China
GSK Investigational Site
Shenyang, China
GSK Investigational Site
Shenzhen, China
GSK Investigational Site
Tianjin, China
GSK Investigational Site
Wuhan, China
GSK Investigational Site
Brno, Czechia
GSK Investigational Site
Hradec Králové, Czechia
GSK Investigational Site
Prague, Czechia
GSK Investigational Site
Marseille, France
GSK Investigational Site
Toulouse, France
GSK Investigational Site
Vanduvre-lEs-Nancy, France
GSK Investigational Site
Mainz, Germany
GSK Investigational Site
Tübingen, Germany
Showing 40 of 122 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.